Navigation Links
Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies.

In a chapter of the text that reviews immunotoxins, Susanna Rybak, Ph.D. summarizes preclinical research indicating that the specificity and potency of ONCONASE improves in a number of tumor models, including non-Hodgkin's lymphoma, when it is conjugated with various antibodies. Dr. Rybak also reviews evidence that implies that ONCONASE may also be effectively targeted to tumors as a conjugate with non-internalizing antibodies, as compared with the internalizing antibodies required by standard plant and bacterial toxins.

"Antibody-targeted ONCONASE is the most potent targeted ribonuclease (RNase) that I have studied," Dr. Rybak said. "While immunotoxins have entered the arsenal of anti-cancer drugs, there have been problems with their clinical use. ONCONASE's excellent performance in preclinical studies makes it a very promising candidate for testing in the clinic."

"It is a great honor to be included in this important industry reference book," added Kuslima Shogen, Alfacell's chairman and chief executive officer. "This work is further evidence of the opportunity that exists for us to build a significant ONCONASE franchise, as a single agent, in combination therapy or as a payload in antibody conjugates. ONCONASE has the potential to be an effective, highly targeted agent for the treatment of various cancers beyond mesothelioma."

For more than 25 years, Dr. Rybak's research has centered on the biology of RNases, antibody engineering and drug targeting. Her laboratory at the National Cancer Institute (NCI) developed the groundwork for RNase-based therapeutics for NHL and breast cancer. Dr. Rybak, who is a member of Alfac ell's scientific advisory board, has been a long-term collaborator with the company.

The Handbook of Therapeutic Antibodies (ed: Stephen Dubel; published by Wiley VCH March 2007) presents an up-to-date and comprehensive review for the development, production and therapeutic application of antibodies. For more information, visit http://www.wiley.com.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are no t limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                    Investor Contact:

     David Schull or Wendy Lau         Andreas Marathovouniotis

     Noonan Russo                      Noonan Russo

     212-845-4271                      212-845-4253

              

     

david.schull@eurorscg.com andreas.marathis@eurorscg.com wendy.lau1@eurorscg.com

CONTACT: Media: David Schull, , or Wendy Lau,, +1-212-845-4271, or Investors: AndreasMarathovouniotis, +1-212-845-4253, , all ofNoonan Russo, for Alfacell Corporation david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com

Web site: http://www.alfacell.com/http://www.wiley.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media C ompany


'"/>




Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
10. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
11. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Global Cervical Dysplasia Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/7/2016)... -- Research and Markets has announced the addition of ... Forecast to 2021" report to their offering. ... , , The immunohistochemistry ... at a CAGR of 7.3% during the forecast period of 2016 to ... and rapidly increasing geriatric population across the globe are the primary driving ...
(Date:12/7/2016)... , Dec. 7, 2016  Palatin Technologies, Inc. ... closed on a previously disclosed underwritten public offering ... Genuity acted as sole book-running manager, Roth Capital ... Markets acted as co-manager for the offering. ... million in net proceeds, allowing us to continue ...
Breaking Medicine Technology:
(Date:12/7/2016)... New York, NY (PRWEB) , ... December 07, ... ... measurable amounts of the drug in their bodies, a researcher at the Icahn ... the journal Pediatric Research. , The study found that when young children are ...
(Date:12/7/2016)... LAKE CITY, UTAH (PRWEB) , ... December 07, ... ... productivity, today announced the release of Smart Device Remote Control through a new ... management across all platforms and strengthens its mobile solutions to help businesses maximize ...
(Date:12/7/2016)... ... December 07, 2016 , ... EnghouseSystems ... purchase price of approximately $17.4 million (net of the cash acquired), subject ... $13.2 million. Headquartered in Barcelona, Spain, Presence is a leading provider of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... It is vital ... is with useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, ... 'need for speed' and the need to operate in a GLP (Good Laboratory Practice) ...
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward Hallowell, ... on social media that offer a rare glimpse into the mind of those people ... New York Times bestselling author, has described people with ADHD as having “Ferrari engines ...
Breaking Medicine News(10 mins):